Thank you, Joe, and good afternoon, everyone. Before I get started, I want to direct you to the earnings presentation on the Masimo website, which covers much of the detail that we will be discussing today. Our first quarter results illustrate our ability to increase earnings even in the face of supply chain issues that limited our shipments and sales growth. The strength in the demand from our customers can be seen in our driver shipments, which met our expectations by reaching 75,700 as we had our third consecutive quarter of driver shipments of approximately 75,000 units. Increased demand for patient monitoring in hospitals has been durable, as these results demonstrate. We have now shipped over 2.3 million technology boards and instruments over the last 10 years. For the first quarter of 2022, we reported revenue of $304 million, representing 2% reported growth and 3% constant currency growth. Our results were adversely affected by certain supply chain issues, which we have addressed. Had this not occurred, we would have exceeded our revenue and earnings expectations for the quarter due to our continued strong customer demand. Moving down the P&L. Our first quarter 2022 non-GAAP gross margin increased 140 basis points to 67.5% compared to 66.1% in the prior year period. Our gross margin improvement was driven by favorable product mix, as we derived a higher proportion of our revenues from adhesive sensors compared to equipment. Our first quarter 2022 non-GAAP operating profit was $70 million or an operating margin of 22.9%. In comparison, first quarter 2021 non-GAAP operating profit was $68 million or an operating margin of 22.9%. Our first quarter 2022 non-GAAP net income was $53 million or $0.93 per diluted share. In comparison, first quarter 2021 non-GAAP income was $52 million or $0.90 per diluted share. Overall, for the first quarter, we achieved earnings growth that was in line with sales growth in the face of supply chain challenges that affected production volume, and our driver shipments have held steady at roughly $75,000, illustrating the strength of our core business. Now I'd like to provide you with an update on our 2022 financial guidance, including expectations for the recently acquired Sound United business, which closed three weeks ago. Due to the acquisition and timing of revenues stemming from supply chain challenges in the first quarter, we are providing consolidated guidance ranges for the second quarter and for the full year. Our guidance incorporates increased foreign currency headwinds from the strengthening of the U.S. dollar against most major currencies. For the second quarter of 2022, we are projecting consolidated revenue of $525 million to $555 million, which includes $180 million to $190 million of revenue for Sound United from the closing of the transaction on April 11 through the end of the quarter. For our Healthcare business, we are projecting $345 million to $365 million of revenue, which includes $4 million of year-over-year currency headwinds. For the first half of the year, this implies a revenue range of $649 million to $669 million for our health care business, which reflects 9% to 12% constant currency growth. Consistent with what Joe mentioned earlier in the call, this outlook illustrates our confidence in recapturing a large portion of the delayed revenues in the second quarter, while being thoughtful about the broader supply chain environment and logistics challenges. Going back to our second quarter guidance. We are projecting consolidated non-GAAP gross margins of 56%, operating margins of 18% and earnings per share ranging from $1.13 to $1.25. Now moving on to our full year 2022 financial guidance. For the full year, we are projecting consolidated revenue of $2 billion to $2.06 billion, which includes $660 million to $700 million of revenue for Sound United from the closing of the transaction on April 11 through the end of the year. For our Healthcare business, we are projecting revenue of $1.34 billion to $1.36 billion, which includes $17 million of year-over-year currency headwinds. This implies a constant currency revenue range of $1.37 billion to $1.377 billion compared to our prior constant currency guidance of $1.357 billion. This update reflects 9.5% to 11% constant currency growth for our health care business. We are also projecting shipments of at least 300,000 technology boards and instruments this year. On a non-GAAP basis, we are projecting gross margin of 56% for our consolidated business, which assumes gross margins of 36% to 37% per Sound United and 66.5% for our health care business. Incorporated in our guidance for the remainder of the year are higher freight and product costs, which we believe will be partially offset by increased manufacturing efficiencies and cost reduction efforts. On a non-GAAP basis, we are projecting an operating margin of 18% to 19% for our consolidated business, which assumes operating margins of 5% to 7% per Sound United and 24.8% for our health care business. It is important to note that Sound United's operating margin guidance includes co-development and co-commercialization investments that will drive the expected benefits of this acquisition. These initiatives will allow us to enter and expand into large and growing markets that are in order of magnitude larger than the markets we serve today. These investments represent roughly 2% of Sound United's revenue. Furthermore, this guidance includes depreciation, amortization and non-cash share-based compensation expenses, which represent approximately 4% of Sound United's revenue. Lastly, the continued strengthening of the U.S. dollar against most major currencies has negatively impacted Sound United's operating margins by a magnitude of 2 percentage points. Moving further down the P&L. Our non-GAAP non-operating expense for the consolidated business is expected to be $18 million in 2022. This is primarily comprised of the interest expense associated with the roughly $600 million drawdown against the new credit facility used to finance the acquisition. We are also projecting a non-GAAP tax rate of 25.3% and weighted average shares outstanding of $58.2 million for the consolidated business. Based on these assumptions, we are projecting a non-GAAP EPS range of $4.46 to $4.73 on a consolidated basis. To summarize, our core health care business is on track to meet or exceed expectations this year, and we are steadfast in our commitment to achieving long-term revenue growth of 8% to 10% for this business. I've never been more excited about our long-term financial future. For additional details on our 2022 financial guidance, please refer to today's earnings presentation within the Investor Relations section of our website at masimo.com. With that, I'll turn the call back to Joe.